A. Kenwright

417 total citations
9 papers, 271 citations indexed

About

A. Kenwright is a scholar working on Rheumatology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Kenwright has authored 9 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Rheumatology, 3 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Kenwright's work include Rheumatoid Arthritis Research and Therapies (4 papers), Bone health and treatments (3 papers) and Influenza Virus Research Studies (2 papers). A. Kenwright is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (4 papers), Bone health and treatments (3 papers) and Influenza Virus Research Studies (2 papers). A. Kenwright collaborates with scholars based in United Kingdom, United States and Denmark. A. Kenwright's co-authors include Adam Platt, Olivier Harari, Robert R. Recker, I. Byrjalsen, Anne‐Christine Bay‐Jensen, M.A. Karsdal, E. J. Czerwiński, Georg Schett, Paul Emery and Gerolamo Bianchi and has published in prestigious journals such as Clinical Infectious Diseases, Annals of the Rheumatic Diseases and Osteoporosis International.

In The Last Decade

A. Kenwright

9 papers receiving 261 citations

Peers

Countries citing papers authored by A. Kenwright

Since Specialization

Citations

This map shows the geographic impact of A. Kenwright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Kenwright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Kenwright more than expected).

Fields of papers citing papers by A. Kenwright

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Kenwright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Kenwright. The network helps show where A. Kenwright may publish in the future.

Co-authorship network of co-authors of A. Kenwright

This figure shows the co-authorship network connecting the top 25 collaborators of A. Kenwright. A scholar is included among the top collaborators of A. Kenwright based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Kenwright. A. Kenwright is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review 2021 ·Prostate Cancer and Prostatic Diseases ·Soroush Rais‐Bahrami, Jason A. Efstathiou, (unknown), (unknown), A. Kenwright, David M. Schuster, Andrew Scarsbrook	11
2	Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS) 2019 ·Clinical Infectious Diseases ·(unknown), (unknown), A. Kenwright, Martin Schutten, Charles A. Boucher, Arnold S. Monto, Barry Clinch, Deepali Kumar, Richard J. Whitley, Jonathan S. Nguyen‐Van‐Tam, Albert D. M. E. Osterhaus, Ron A. M. Fouchier, Pieter L.A. Fraaij	21
3	Oseltamivir in pregnancy and birth outcomes 2018 ·BMC Infectious Diseases ·Véra Ehrenstein, Nickolaj Risbo Kristensen, Brigitta U. Monz, Barry Clinch, A. Kenwright, Henrik Toft Sørensen	19
4	Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis 2012 ·The Pharmacogenomics Journal ·(unknown), Aruna T. Bansal, (unknown), Søren Germer, Ryma Benayed, Laurent Essioux, (unknown), A. B. Begovich, Andrew Hemmings, A. Kenwright, Kimberly E. Taylor, Ruchi Upmanyu, Paul Cutler, Olivier Harari, Jonathan Marchini, Lindsey A. Criswell, Adam Platt	39
5	IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study (NCT00106522) 2012 ·Seminars in Arthritis and Rheumatism ·M.A. Karsdal, Georg Schett, Paul Emery, Olivier Harari, I. Byrjalsen, A. Kenwright, Anne‐Christine Bay‐Jensen, Adam Platt	79
6	OP0127 Identification of serological biomarker profiles associated with early response to tocilizumab in rheumatoid arthritis 2012 ·Annals of the Rheumatic Diseases ·Anne‐Christine Bay‐Jensen, I. Byrjalsen, A. Kenwright, Adam Platt, M.A. Karsdal	6
7	Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study 2011 ·Osteoporosis International ·Paul D. Miller, Robert R. Recker, J.-Y. Reginster, B.J. Riis, E. J. Czerwiński, Daiva Masanauskaite, A. Kenwright, R Lorenc, J. A. Stakkestad, Péter L. Lakatos	43
8	Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension 2011 ·Osteoporosis International ·Gerolamo Bianchi, E. J. Czerwiński, A. Kenwright, (unknown), Robert R. Recker, Dieter Felsenberg	40
9	TOCILIZUMAB IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: EFFICACY DATA FROM THE PLACEBO-CONTROLLED 12-WEEK PART OF THE PHASE III TENDER TRIAL 2011 ·Data Archiving and Networked Services (DANS) ·Jeffrey Chaitow, Fabrizio De Benedetti, Hermine I. Brunner, Nicolino Ruperto, (unknown), Karen Murray, Rayfel Schneider, Patricia Woo, (unknown), A. Kenwright, Alberto Martini, D. Lovell	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact